Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765741 | 0.91 | PIM1 (0.48) | CNR1ADORA1ADORA2AADORA2BMAOB | |
| SCHEMBL6770608 | 0.87 | ADORA1 (0.46) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6775541 | 0.84 | ADORA1 (0.52) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6768976 | 0.84 | ADORA2A (0.60) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6771685 | 0.83 | HPGD (0.52) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6766048 | 0.82 | ADORA2A (0.57) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6769704 | 0.81 | ADORA1 (0.49) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6989458 | 0.81 | ADORA1 (0.67) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6774916 | 0.80 | ADORA1 (0.51) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 | |
| SCHEMBL6768405 | 0.80 | BRD4 (0.46) | ADORA1ADORA2AADORA2BMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6750232-B2 | ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS | EISAI CO., LTD. (JP) | 2004-06-15 | — | — | US | disclosed |
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| EP-1308441-A1 | 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS | Eisai Co., Ltd. (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006082-A1 | 2-Aminopyridine compounds and use thereof as drugs | ADORA1, ADORA2B, ADORA2A | IGF1R 1964/4885CNR1 25/4885ADORA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.